Acute hemodynamic improvement by pacing in patients with severe congestive heart failure

A Auricchio1, R W Salo

  • 1Department of Cardiology, University Hospital, Magdeburg, Germany.

Insights

Optimizing dual chamber pacing in congestive heart failure (CHF) patients improves hemodynamics. Individualized pacing strategies, focusing on filling time and ventricular activation, are key for better cardiac function.

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Heart Failure Management

Background:

  • Dual chamber pacing for congestive heart failure (CHF) has yielded conflicting results since 1991.
  • Understanding the precise mechanisms of pacing benefit is incomplete.
  • Potential mechanisms include improved filling time, reduced mitral regurgitation, optimized atrioventricular delay, and normalized ventricular activation.

Purpose of the Study:

  • To investigate the acute hemodynamic effects of individually optimized dual chamber pacing in CHF patients.
  • To explore the relationship between pacing site (right ventricle vs. left ventricle) and hemodynamic response.
  • To identify the primary mechanisms driving pacing-induced improvements in cardiac function.

Main Methods:

  • Acute pacing studies were performed on nine CHF patients (NYHA Class II-III to IV).
  • Measurements included conduction times, high-fidelity aortic pressure, and mitral/aortic velocities during various pacing modes (RV, LV, biventricular) at optimal AV delays.
  • Analysis compared pacing conditions to baseline sinus rhythm.

Main Results:

  • Six out of nine patients showed increased mean pulse pressure with RV or LV pacing at optimal AV delay.
  • Maximum aortic pulse pressure was achieved with unpaced atria (RV pacing: +8% vs. sinus; LV pacing: +0% vs. sinus).
  • Pacing site dependency was observed (4 RV, 3 LV best), and restrictive filling patterns converted to nonrestrictive in 2/4 patients.

Conclusions:

  • Individually optimized pacing acutely benefits patient hemodynamics in CHF.
  • Key mechanisms include increased filling time, optimized mechanical atrioventricular delay, and normalized intraventricular activation.
  • Atrial pacing is less effective than atrial sensing modes in patients with a functional sinus node.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...